Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions

Document Type

Article

Publication Date

1-17-2023

Abstract

Urinary bladder cancer (UBC) holds a potentially profound social burden and afects over 573,278 new cases annually. The disease’s primary risk factors include occupational tobacco smoke exposure and inherited genetic susceptibility. Over the past 30 years, a number of treatment modalities have emerged, including cisplatin, a platinum molecule that has demonstrated efectiveness against UBC. Nevertheless, it has severe dose-limiting side efects, such as nephrotoxicity, among others. Since intracellular accumulation of platinum anticancer drugs is necessary for cytotoxicity, decreased uptake or enhanced efux are the root causes of platinum resistance and response failure. Evidence suggests that genetic variations in any transporter involved in the entry or efux of platinum drugs alter their kinetics and, to a signifcant extent, determine patients’ responses to them. This review aims to consolidate and describe the major transporters and their polymorphic variants in relation to cisplatin-induced toxicities and resistance in UBC patients. We concluded that the efux transporters ABCB1, ABCC2, SLC25A21, ATP7A, and the uptake transporter OCT2, as well as the organic anion uptake transporters OAT1 and OAT2, are linked to cisplatin accumulation, toxicity, and resistance in urinary bladder cancer patients. While suppressing the CTR1 gene’s expression reduced cisplatin-induced nephrotoxicity and ototoxicity, inhibiting the expression of the MATE1 and MATE2-K genes has been shown to increase cisplatin’s nephrotoxicity and resistance. The roles of ABCC5, ABCA8, ABCC10, ABCB10, ABCG1, ATP7B, ABCG2, and mitochondrial SLC25A10 in platinum-receiving urinary bladder cancer patients should be the subject of further investigation.

Link to Full Text

Share

COinS